845550-71-2

Upstream product

• 85356-68-9 1-bromo-4-(2-iodoethyl)benzene 
• 1068-90-2 2-acetylaminomalonic acid diethyl ester 
• 5463-92-3 2-acetylamino-2-phenylethylmalonic acid diethyl ester 
• 15121-91-2 diethyl 2-acetylamino-2-(2-oxo-2-phenylethyl)malonate 
• 532-27-4 1-chloroacetophenone 
• 71-43-2 benzene 
• 4654-39-1 4-bromophenethanol 
• 1746-28-7 1-bromo-4-(2-bromoethyl)benzene 

Downstream Products

• 956037-25-5 N-(4-(4-bromophenyl)-1-hydroxy-2-(hydroxymethyl)butan-2-yl)acetamide 
• 845550-72-3 2-acetamido-2-[2-(4-bromophenyl)ethyl]propane-1,3-diol diacetate 

Relevant academic research and scientific papers

Convergent Synthesis of Immune Inhibitor IMMH002

A convergent synthesis of IMMH002 in 36% overall yield starting from bromobenzene is described with a key Suzuki-Miyaura cross-coupling reaction used to provide a crucial intermediate. The route does not require column chromatography and solves the most intractable quality problem caused by a homologue by-product in the original linear synthesis. Furthermore, reducing the use of Lewis acid mediated reactions improves the environmental impact of the synthesis and reduces overall waste. The new route described herein is more efficient, convenient, reliable, and economically more viable when compared to the previously reported linear route.

Preparation method of pusaimode (Chinese name)

The invention discloses a preparation method of pusaimode. Bromo-benzene is used as an initial raw material to prepare pusaimode by adopting a convergent synthesis route. The yield of the preparationmethod is high, the cost is low, the amount of generated waste water, waste gas, and waste solids is low, the operation is convenient, and the application value is high.

Preparation method of aituomode

The invention discloses a preparation method of aituomode. Bromo-benzene is used as an initial raw material to prepare aituomode by adopting a convergent synthesis route. The yield of the preparationmethod is high, the cost is low, the amount of generated waste water, waste gas, and waste solids is low, the operation is convenient, and the application value is high.

Preparation method of aituomode

The invention discloses a preparation method of aituomode. Bromo-benzene and benzene are used as initial raw materials to prepare aituomode by adopting a convergent synthesis route. The yield of the preparation method is high, the cost is low, the amount of generated waste water, waste gas, and waste solids is low, the operation is convenient, and the application value is high.

Preparation method of pusaimode (Chinese name)

The invention discloses a preparation method of pusaimode. Bromo-benzene and benzene are used as initial raw materials to prepare pusaimode by adopting a convergent synthesis route. The yield of the preparation method is high, the cost is low, the amount of generated waste water, waste gas, and waste solids is low, the operation is convenient, and the application value is high.

Containing five-membered amino propylene glycol compound, its preparation method and medical use thereof

The present invention relates to a class of five-membered aromatic heterocycle-containing amino propanediol compounds, a preparation method, drug compositions containing the compounds, and pharmaceutical preparations thereof, and uses of the compounds as

Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design

We have discovered a series of triazole/oxazole-containing 2-substituted 2-aminopropane-1,3-diol derivatives as potent and selective S1P1 agonists (prodrugs) based on pharmacophore-guided rational design. Most compounds showed high affinity and

Removal of sphingosine 1-phosphate receptor-3 (S1P3) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P1 agonists with reduced effect on heart rate

A series of 2-substituted 2-aminopropane-1,3-diols having a biphenyl moiety and their phosphate esters were synthesized to obtain sphingosine 1-phosphate receptor-1 (S1P1) receptor agonists with potent immunomodulatory activity accompanied by little or no effect on heart rate. Many of the synthesized compounds sufficiently decreased the number of peripheral blood lymphocytes. Some of the phosphates had potent agonism at S1P1 but no agonism at S1P3, which had been reported to be a receptor responsible for heart rate reduction. Although high S1P1/S1P 3 selectivity was considered to be favorable to reduce the effect on heart rate, almost all the phosphates showed a remarkable heart rate lowering effect in vivo. The results suggest that other factors in addition to S1P 3 agonism should be responsible for the heart rate reduction caused by S1P1 agonists. Only 2-amino-2-[2-[2′-fluoro-4′-(4- methylphenylthio)biphenyl-4-yl]ethyl]propane-1,3-diol (6d) was identified as a desired S1P1 receptor agonist having both the immunomodulatory activity and an attenuated effect on heart rate by a unique screening flow using in vivo evaluating systems primarily.

2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES

The present invention provides a novel compound having few side effects such as bradycardia and the like and having superior peripheral blood lymphocyte-decreasing effect. The present invention provides a 2-aminobutanol compound represented by the following formula (I) wherein R1 is a hydrogen atom or P(=O)(OH)2, R2 is an alkyl having 1 to 4 carbon atoms optionally substituted by hydroxyl group(s) or optionally substituted by halogen atom(s), R3 is a hydrogen atom; a halogen atom; cyano; an alkyl having 1 to 4 carbon atoms optionally substituted by halogen atom(s); or an acyl having 2 to 5 carbon atoms optionally substituted by halogen atom(s), X is an oxygen atom, a sulfur atom, carbonyl or NR4 wherein R4 is a hydrogen atom or an alkyl having 1 to 4 carbon atoms, Ar1 is an optionally substituted arylene or an optionally substituted heteroarylene, and Ar2 is an optionally substituted aryl or an optionally substituted heteroaryl, provided that when X is an oxygen atom, Ar1 is phenylene and Ar2 is phenyl, then the phenyl for Ar2 should be substituted, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof, as well as a production method of the above-mentioned 2-aminobutanol compound.

BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY

The invention is directed to a bi-aryl compound having a unique immunomodulating activity, a process for a preparation thereof, a pharmaceutical composition containing the same, and a method of preventing or treating disorders or diseases mediated by T lymphocytes by administering the compound to a subject in need of treatment.